Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 11
Submit an article Journal homepage
494
Views
11
CrossRef citations to date
0
Altmetric
Reviews

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

Monika EngelhardtDepartment of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyCorrespondence[email protected]
,
Josefina UdiDepartment of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
,
Martina KleberDepartment of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
,
Andrew SpencerMalignant Hematology and Stem Cell Transplantation Service, Alfred Hospital, Victoria, Australia
,
Alberto RocciDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
,
Stefan KnopDepartment of Internal Medicine, University Hospital Würzburg, Würzburg, Germany
,
Benedetto BrunoDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
,
Sara BringhenDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
,
José A. Pérez-SimónHospital Clínico/Centro de Investigación del Cáncer, Salamanca, Spain
,
Sonja ZweegmanDepartment of Hematology, VU University Medical Center, Amsterdam (VUMC), The Netherlands
,
Christoph DriessenDepartment of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
,
Francesca PatriarcaDivision of Hematology and Transplant Unit ‘Carlo Melzi’, Department of Morphological and Clinical Research, University of Udine, Italy
,
Martin GramatzkiDivision of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany
,
Evangelos TerposDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
,
Orhan SezerDepartment of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
,
Martin KropffDepartment of Medicine/Hematology and Oncology, University of Münster, Münster, Germany
,
Christian StrakaDepartment of Hematology and Oncology, Argirov Klinik Starnberger See, Berg, Germany
,
Hans E. JohnsenAalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
,
Anders WaageDepartment of Hematology, St. Olavs Hospital and NTNU, Trondheim, Norway
,
Martin BoegstedAalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
,
Henk LokhorstDepartment of Hematology, Utrecht University Medical Center, Utrecht (UMCU), The Netherlands
,
Roman HájekDepartment of Internal Medicine, University Hospital Brno, Brno, Czech Republic
,
Gareth MorganDepartment of Hematology/Oncology, The Leukemia and Myeloma Program, Wimbledon, UK
,
Mario BoccadoroDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
,
Heinz Ludwig1st Medical Department and Oncology, Wilhelminenspital Wien, Vienna, Austria
,
Michele Cavo ‘Seràgnoli’ Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy
,
Aaron PolliackDepartment of Hematology, Hadassah University Hospital, Jerusalem, Israel
,
Pieter SonneveldDepartment of Hematology, Rotterdam, The Netherlands
,
Hermann EinseleDepartment of Internal Medicine, University Hospital Würzburg, Würzburg, Germany
&
Antonio PalumboDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
 show all
Pages 2006-2011 | Received 12 Aug 2010, Accepted 13 Aug 2010, Published online: 31 Aug 2010

References

  • Einsele H, Liebisch P, Langer C, et al Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Blood 2009;114(Suppl. 1): Abstract 131.
  • Eleutherakis-Papaiakovou E, Christoulas D, Migkou M, et al The impact of different pre-transplant regimens including novel agents on peripheral blood mobilization, harvest, response and survival in patients undergoing ASCT for multiple myeloma. A single-center experience in 210 patients. Blood 2009;114(Suppl. 1): Abstract 2279.
  • Palumbo A, Cavallo F, Yehuda D-B, et al A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis. Blood 2009;114(Suppl. 1): Abstract 350.
  • Engelhardt M, Kleber M, Udi J, et al Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010;51:1424–1443.
  • Minnema M-C, van der Holt B, Kersten M-J, et al First interim analysis of HOVON 76: lenalidomide maintenance following non myeloablative allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2009; 114(Suppl. 1): Abstract 2285.
  • Edgren G, Bagnardi V, Bellocco R, et al Pattern of declining hemoglobin concentration before cancer diagnosis. Int J Cancer 2010;127:1429–1436.
  • Ludwig H, Endler G, Hübl W, Klement B, Cushway T. High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients. Haematologica 2010;95(Suppl. 2): Abstract 1819.
  • Anker SD, Comin Colet J, Filippatos G, et al Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.
  • Avet-Loiseau H, Durie B, Haessler J, et al Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients. Blood 2009;114(Suppl. 1): Abstract 743.
  • Corthals S-L, Goldschmidt H, Johnson D-C, et al Genetic associations with therapy response in the HOVON-65/GMMG-HD4 trial in patients with multiple myeloma. Blood 2009;114(Suppl. 1): Abstract 1790.
  • Kapoor P, Rajkumar S-V, Dispenzieri A, et al Melphalan and prednisone (MP) versus melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials. Blood 2009;114(Suppl. 1): Abstract 615.
  • Vij R, Siegel D-S, Kaufman J-L, et al Results of an ongoing open-label, phase II study of cerfilzomib in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol 2010;28(Suppl.): Abstract 8000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.